

CITATION REPORT

List of articles citing

Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease

DOI: 10.3233/jad-2012-111661

Journal of Alzheimer's Disease, 2012, 30, 943-61.

Source: <https://exaly.com/paper-pdf/54071084/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
126	Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice. 2012 , 3, e448		51
125	Neuroprotection by dietary restriction and the PPAR transcription complex. 2012 , 3,		1
124	Type 2 Diabetes Mellitus and Alzheimer's Disease: from physiopathology to treatment implications. 2013 ,		16
123	Hippocampal calcium dysregulation at the nexus of diabetes and brain aging. <i>European Journal of Pharmacology</i> , 2013 , 719, 34-43	5.3	22
122	Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons. 2013 , 126, 685-95		27
121	Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies. 2013 , 42, 489-501		33
120	From a Cell's Viewpoint: Targeting Mitochondria in Alzheimer's disease. 2013 , 10, e91-e98		2
119	Mitochondrial diseases of the brain. 2013 , 63, 1-29		305
118	Using genetics to enable studies on the prevention of Alzheimer's disease. 2013 , 93, 177-85		60
117	Integrating transcriptomics with metabolic modeling predicts biomarkers and drug targets for Alzheimer's disease. 2014 , 9, e105383		42
116	Aged rats are hypo-responsive to acute restraint: implications for psychosocial stress in aging. 2014 , 6, 13		28
115	Impaired insulin signaling and mechanisms of memory loss. 2014 , 121, 413-49		31
114	Partially purified <i>Peucedanum japonicum</i> Thunb extracts exert anti-obesity effects in vitro. 2014 , 30, 575-83		21
113	Modulation of inflammation in transgenic models of Alzheimer's disease. 2014 , 11, 25		86
112	Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions. 2014 , 14, 476		102
111	Insulin resistance in Alzheimer's disease. 2014 , 72 Pt A, 92-103		78
110	Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system. 2014 , 66, 815-68		105

109	PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption. 2014 , 86, 397-407	66
108	A systems biology investigation of neurodegenerative dementia reveals a pivotal role of autophagy. 2014 , 8, 65	17
107	Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. 2014 , 1842, 1693-706	230
106	Nuclear receptors in neurodegenerative diseases. 2014 , 72 Pt A, 104-16	67
105	The mitochondrial uncoupler DNP triggers brain cell mTOR signaling network reprogramming and CREB pathway up-regulation. 2015 , 134, 677-92	40
104	Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity. 2015 , 10, e0123864	31
103	Therapeutic Actions of the Thiazolidinediones in Alzheimer's Disease. 2015 , 2015, 957248	33
102	Metabolic roles of PGC-1 α and its implications for type 2 diabetes. 2015 , 41, 347-57	48
101	Electrophilic Derivatives of Omega-3 Fatty Acids for the Cure and Prevention of Neurodegenerative Disorders. 2015 , 325-339	
100	Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. 2015 , 14, 926-944	187
99	Caffeic acid improves memory impairment and brain glucose metabolism via ameliorating cerebral insulin and leptin signaling pathways in high-fat diet-induced hyperinsulinemic rats. 2015 , 77, 24-33	14
98	Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor α Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice. 2015 , 290, 21591-602	58
97	Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents. 2015 , 38, 2106-19	94
96	Expression regulation and targeting of the peroxisome proliferator-activated receptor α following electrically-induced status epilepticus. 2015 , 604, 151-6	4
95	Central activation of PPAR-gamma ameliorates diabetes induced cognitive dysfunction and improves BDNF expression. 2015 , 36, 1451-61	75
94	Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice. 2015 , 122, 593-606	41
93	Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies. 2016 , 6,	24
92	T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 51, 123-38	4-3 29

91	Cigarette smoking impairs nitric oxide-mediated cerebral blood flow increase: Implications for Alzheimer's disease. 2016 , 131, 223-32		34
90	Genetic Deletion of Neuronal PPAR α Enhances the Emotional Response to Acute Stress and Exacerbates Anxiety: An Effect Reversed by Rescue of Amygdala PPAR α Function. 2016 , 36, 12611-12623		36
89	Influence of metformin on mitochondrial subproteome in the brain of apoE knockout mice. <i>European Journal of Pharmacology</i> , 2016 , 772, 99-107	5:3	8
88	Shrinkage-based diagonal Hotelling β tests for high-dimensional small sample size data. 2016 , 143, 127-142		17
87	Bioinformatics methods in drug repurposing for Alzheimer's disease. 2016 , 17, 322-35		50
86	Intranasal Insulin Improves Age-Related Cognitive Deficits and Reverses Electrophysiological Correlates of Brain Aging. 2016 , 71, 30-9		54
85	The Role of Oxidized Cholesterol in Diabetes-Induced Lysosomal Dysfunction in the Brain. 2016 , 53, 2287-96		20
84	Experimentally induced diabetes worsens neuropathology, but not learning and memory, in middle aged 3xTg mice. 2017 , 322, 280-287		19
83	Astragaloside IV, a Natural PPAR α Agonist, Reduces A β Production in Alzheimer's Disease Through Inhibition of BACE1. 2017 , 54, 2939-2949		39
82	Cognitive function and insulin resistance in elderly patients with type 2 diabetes. 2017 , 39, 259-263		12
81	Combination treatment with leptin and pioglitazone in a mouse model of Alzheimer's disease. 2017 , 3, 92-106		25
80	A novel approach to analyze lysosomal dysfunctions through subcellular proteomics and lipidomics: the case of NPC1 deficiency. 2017 , 7, 41408		63
79	Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease. 2017 , 7, 42270		57
78	Therapeutic potential of nuclear receptor agonists in Alzheimer's disease. 2017 , 58, 1937-1949		43
77	GD-RDA: A New Regularized Discriminant Analysis for High-Dimensional Data. 2017 , 24, 1099-1111		6
76	Pioglitazone ameliorates A β 2 deposition in rats with diet-induced insulin resistance associated with AKT/GSK3 β activation. <i>Molecular Medicine Reports</i> , 2017 , 15, 2588-2594	2:9	22
75	Glucose tolerance and insulin sensitivity are impaired in APP/PS1 transgenic mice prior to amyloid plaque pathogenesis and cognitive decline. 2017 , 88, 9-18		39
74	Insulin resistance in Alzheimer's disease. 2017 , 183, 26-40		64

73	Suppression of adiponectin receptor 1 promotes memory dysfunction and Alzheimer's disease-like pathologies. 2017 , 7, 12435		31
72	Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer's Disease. 2017 , 9, 118		72
71	The Novel Implication of Androgen in Diabetes-induced Alzheimer's Disease. 2017 , 6, 66		1
70	Precision pharmacology for Alzheimer's disease. 2018 , 130, 331-365		60
69	Evidence for altered insulin receptor signaling in Alzheimer's disease. 2018 , 136, 202-215		28
68	FK506-Binding Protein 12.6/1b, a Negative Regulator of [Ca], Rescues Memory and Restores Genomic Regulation in the Hippocampus of Aging Rats. 2018 , 38, 1030-1041		14
67	Targeting Insulin for Alzheimer's Disease: Mechanisms, Status and Potential Directions. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S427-S453	4-3	14
66	Disruption of leptin signalling in a mouse model of Alzheimer's disease. 2018 , 33, 1097-1110		14
65	Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. 2018 , 48, 52-108		46
64	PPAR α agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies. 2018 , 13, 5577-5590		31
63	Pioglitazone is superior to quetiapine, clozapine and tamoxifen at alleviating experimental autoimmune encephalomyelitis in mice. 2018 , 321, 72-82		10
62	PPARs and Energy Metabolism Adaptation during Neurogenesis and Neuronal Maturation. 2018 , 19,		9
61	Honokiol Ameliorates Amyloidosis and Neuroinflammation and Improves Cognitive Impairment in Alzheimer's Disease Transgenic Mice. 2018 , 366, 470-478		16
60	CDK5 Participates in Amyloid- β Production by Regulating PPAR β Phosphorylation in Primary Rat Hippocampal Neurons. <i>Journal of Alzheimer's Disease</i> , 2019 , 71, 443-460	4-3	5
59	Activated PPAR α Abrogates Misprocessing of Amyloid Precursor Protein, Tau Missorting and Synaptotoxicity. 2019 , 13, 239		5
58	. 2019 ,		0
57	Activation of PPAR α Attenuates the Expression of Physical and Affective Nicotine Withdrawal Symptoms through Mechanisms Involving Amygdala and Hippocampus Neurotransmission. 2019 , 39, 9864-9875		17
56	Mitochondrial Dysfunction in Alzheimer's Disease and Progress in Mitochondria-Targeted Therapeutics. 2019 , 6, 88-102		12

55	Pathological and cognitive changes in patients with type 2 diabetes mellitus and comorbid MCI and protective hypoglycemic therapies: a narrative review. 2019 , 30, 757-770	1
54	Identification of Temporal Characteristic Networks of Peripheral Blood Changes in Alzheimer's Disease Based on Weighted Gene Co-expression Network Analysis. 2019 , 11, 83	12
53	Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases). 2019 , 391-442	1
52	Reverting Metabolic Dysfunction in Cortex and Cerebellum of APP/PS1 Mice, a Model for Alzheimer's Disease by Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma (PPAR γ) Agonist. 2019 , 56, 7267-7283	19
51	GLUT4: A central player in hippocampal memory and brain insulin resistance. 2020 , 323, 113076	32
50	Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models. 2020 , 178, 108225	2
49	Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones. 2020 , 155, 37-64	10
48	Diabetes and dementia - the two faces of Janus. 2020 , 5, e186-e197	3
47	Metabolic Profiling of Female Tg2576 Mouse Brains Provides Novel Evidence Supporting Intranasal Low-Dose Pioglitazone for Long-Term Treatment at an Early Stage of Alzheimer's Disease. 2020 , 8,	6
46	Type 2 Diabetes Mellitus Drugs for Alzheimer's Disease: Current Evidence and Therapeutic Opportunities. 2020 , 26, 597-614	16
45	Quercetin-3-O-Glucuronide Alleviates Cognitive Deficit and Toxicity in A β -Induced AD-Like Mice and SH-SY5Y Cells. 2021 , 65, e2000660	9
44	Lipid alterations in human frontal cortex in ALS-FTLD-TDP43 proteinopathy spectrum are partly related to peroxisome impairment. 2021 , 47, 544-563	7
43	Targeting Insulin Resistance to Treat Cognitive Dysfunction. 2021 , 58, 2672-2691	6
42	Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer's disease. 2021 , 11, 179	2
41	Inflammation and Insulin Resistance as Risk Factors and Potential Therapeutic Targets for Alzheimer's Disease. 2021 , 15, 653651	6
40	Tackling Alzheimer's Disease with Existing Drugs: A Promising Strategy for Bypassing Obstacles. 2021 , 28, 2305-2327	0
39	The Role of PGC1 α in Alzheimer's Disease and Therapeutic Interventions. 2021 , 22,	2
38	Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypotheses. <i>Journal of Alzheimer's Disease</i> , 2021 , 82, 71-105	4-3 7

37	Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment. 2021 , 22,		6
36	Reassessment of Pioglitazone for Alzheimer's Disease. 2021 , 15, 666958		5
35	Towards development of a novel screening method for identifying Alzheimer's disease risk: Raman spectroscopy of blood serum and machine learning. 2021 , 254, 119603		4
34	Enhancement of Insulin/PI3K/Akt Signaling Pathway and Modulation of Gut Microbiome by Probiotics Fermentation Technology, a Kefir Grain Product, in Sporadic Alzheimer's Disease Model in Mice. 2021 , 12, 666502		3
33	Parallel Framework for Inferring Genome Scale Gene Regulatory Networks.		
32	Honokiol Restores Microglial Phagocytosis by Reversing Metabolic Reprogramming. <i>Journal of Alzheimer's Disease</i> , 2021 , 82, 1475-1485	4.3	1
31	From obesity to Alzheimer's disease through insulin resistance. 2021 , 35, 108026		7
30	Inhibition of mitochondrial pyruvate carrier 1 by lapatinib ditosylate mitigates Alzheimer's-like disease in D-galactose/ovariectomized rats. 2021 , 150, 105178		1
29	Therapeutic Advantages of Dual Targeting of PPAR- α and PPAR- γ in an Experimental Model of Sporadic Alzheimer's Disease. 2018 , 5,		6
28	The central role of AMP-kinase and energy homeostasis impairment in Alzheimer's disease: a multifactor network analysis. 2013 , 8, e78919		29
27	Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease. 2015 , 14, 684-96		11
26	Intravenous immunoglobulin reduces tau pathology and preserves neuroplastic gene expression in the 3xTg mouse model of Alzheimer's disease. <i>Current Alzheimer Research</i> , 2014 , 11, 655-63	3	10
25	Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update. <i>Current Neuropharmacology</i> , 2019 , 17, 232-246	7.6	33
24	Ginsenoside Rg1 reduces β -amyloid levels by inhibiting CD κ 5-induced PPAR γ phosphorylation in a neuron model of Alzheimer's disease. <i>Molecular Medicine Reports</i> , 2020 , 22, 3277-3288	2.0	3
23	Repurposing old molecules for new indications: Defining pillars of success from lessons in the past. <i>European Journal of Pharmacology</i> , 2021 , 912, 174569	5.3	3
22	Enhanced anti-amyloid effect of combined leptin and pioglitazone in APP/PS1 transgenic mice.		1
21	Brain Expression, Physiological Regulation and Role in Motivation and Associative Learning of Peroxisome Proliferator-activated Receptor α <i>Neuroscience</i> , 2021 , 479, 91-106	3.9	1
20	Pioglitazone improves deficits of Fmr1-KO mouse model of Fragile X syndrome by interfering with excessive diacylglycerol signaling.		1

19	Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease. <i>American Journal of Neurodegenerative Disease</i> , 2016 , 5, 1-28	2.5	13
18	Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease in focal cerebral ischemic rats. <i>American Journal of Neurodegenerative Disease</i> , 2016 , 5, 102-30	2.5	18
17	Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation.. <i>European Journal of Pharmacology</i> , 2022 , 919, 174800	5.3	1
16	Dysmetabolism and Neurodegeneration: Trick or Treat?. <i>Nutrients</i> , 2022 , 14,	6.7	0
15	Therapeutic strategies for tauopathies and drug repurposing as a potential approach.. <i>Biochemical Pharmacology</i> , 2022 , 198, 114979	6	1
14	The potential benefit of leptin therapy against amyotrophic lateral sclerosis (ALS).. <i>Brain and Behavior</i> , 2021 , e2465	3.4	1
13	Data_Sheet_1.ZIP. 2019 ,		
12	Image_1.tif. 2019 ,		
11	Image_2.tif. 2019 ,		
10	Image_3.tif. 2019 ,		
9	Image_4.jpg. 2019 ,		
8	Data_Sheet_1.pdf. 2019 ,		
7	A Pathophysiological Intersection of Diabetes and Alzheimer's Disease. 2022 , 23, 11562		1
6	Development of Dementia in Type 2 Diabetes Patients: Mechanisms of Insulin Resistance and Antidiabetic Drug Development. 2022 , 11, 3767		0
5	A generic parallel framework for inferring large-scale gene regulatory networks from expression profiles: application to Alzheimer's disease network.		0
4	Revealing genetic links of Type 2 diabetes that lead to the development of Alzheimer's disease. 2022 , e12202		0
3	Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke. 2023 , 100, e1799-e1811		0
2	Geroprotective interventions in the 3xTg mouse model of Alzheimer's disease.		0

- 1 Selective PPAR-Delta/PPAR-Gamma Activation Improves Cognition in a Model of Alzheimer's Disease. **2023**, 12, 1116

o